Perrigo Company plc and its co-development partner Aveva Drug Delivery Systems, Inc., an Apotex Company, announced the prescription pharmaceutical launch of scopolamine 1.5 mg transdermal system patch, the AB rated generic equivalent to Transderm Scop (scopolamine 1.5 mg).
Transderm Scop (scopolamine 1.5 mg) transdermal system patch is an anticholinergic indicated for the prevention of nausea and vomiting associated with motion sickness and recovery from anesthesia after surgery in adults. Annual market sales for the 12 months ending May 2017 were approximately $158 million.
Perrigo executive vice president and president Rx Pharmaceuticals John Wesolowski stated, "I would like to thank the R&D and regulatory teams for their efforts to bring this difficult to manufacture product to market. This launch is another example of our ability to deliver complex generic products to patients at more affordable prices."